Bernstein raises Cigna stock price target on specialty pharmacy growth
Bernstein raised its price target for Cigna (NYSE:CI) to $387, citing growth in specialty pharmacy. Cigna set 2026-2030 targets, including 10-14% adjusted earnings growth. Q2 2026 earnings beat expectations, with $7.78 EPS and $71.7B revenue. Analysts have mixed outlooks, with UBS targeting $400 and Evercore ISI at $290.
How this was made
The 30-second read
Why it matters
The guidance lifts earnings expectations, prompting analysts to raise price targets and reaffirm buy ratings.
Market read
New guidance and analyst upgrade create a short‑term bullish catalyst for CI.
What to watch
Potential regulatory pressure on PBM margins could offset specialty gains.
Background
Cigna's investor day presented multi‑year targets, a $3 bn AI efficiency plan, and revised margins for Evernorth and Cigna Healthcare.
Ticker impact
Bernstein raised its price target on Cigna (CI) to $387 after the company's investor day disclosed new 2026‑2030 earnings guidance and a $3 bn AI savings plan.
likely upward pressure as the market prices in stronger specialty pharmacy outlook and higher target price.
The fresh guidance and upgraded target are primary disclosures that were not public before the investor day, providing a clear catalyst for short‑term buying.
Market effects
Specialty pharmacy and health‑care services sectors may see broader optimism.
U.S. health‑care equities could benefit from the positive outlook.
Limited to U.S. markets; no direct global ripple.
Counterpoint
If specialty pharmacy growth stalls, the higher target may be premature.
Key entities
- companyCigna
U.S. health services insurer and pharmacy benefits manager.
- analyst_firmBernstein
Equity research firm that upgraded Cigna.
